[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C, Lavarda M, Jarchum G, Finkelberg AB: Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. Med Oral Patol Oral Cir Bucal; 2009 Mar;14(3):E108-13
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment.
  • Several studies have shown how cytostatics may cause hypofunction of salivary glands but failed to elucidate any potentially related side effects.
  • Keeping in mind the sialochemical assistance and the role of saliva on the homeostasis of the stomatognathic system, the aim of this study was to establish potential gland disorders in patients submitted to 5- Fluorouracil (5-Fu) and Leucovorin calcium (LV) as well as their correlation with certain oral health disorders that diminish the quality of life.
  • Twenty-five patients diagnosed with colon cancer at an initial, intermediate and late phase submitted to specifically devised therapy were assessed.
  • RESULTS: Basal and stimulated flow dropped in the intermediate stage.
  • Stimulated saliva pH decreased during treatment.
  • Löe and Silness rates as well as simplified bleeding increased during therapy but reverted by the end of the treatment.
  • CONCLUSION: This treatment caused functional salivary gland disorders as evidenced by basal and stimulated hyposialia, and acidification of stimulated saliva pH during the intermediate phase.
  • Recovery of bleeding and Löe and Silness rates may point to a transient inflammatory effect associated to a decrease in salivary flow.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Fluorouracil / adverse effects. Leucovorin / adverse effects. Salivary Gland Diseases / chemically induced. Vitamin B Complex / adverse effects

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242388.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR: A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer; 2010 Jan 15;116(2):362-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group.
  • BACKGROUND: Salivary gland cancers are rare, histologically diverse, and varied in their biologic behavior and responsiveness to systemic therapy.
  • To the authors' knowledge, there currently is no standard chemotherapy for these tumors, but cisplatin-based regimens are often used.
  • METHODS: Fit, consenting adult patients had advanced, metastatic, or locoregionally recurrent salivary gland cancer (any histologic subtype) that was not suitable for radiation or surgery.
  • Therapy was comprised of gemcitabine at a dose of 1000 mg/m(2) administered intravenously on Days 1 and 8, and cisplatin at a dose of 70 mg/m(2) on Day 2, of a 21-day cycle.
  • If carboplatin was substituted, it was administered on Day 1, targeted to an area under the concentration-time curve of 5 mg/mL/s.
  • A 2-stage design was used, with a response rate of 45% required to declare the regimen active.
  • CONCLUSIONS: This regimen did not meet the predefined criteria to be declared active in advanced salivary gland cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924794.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, Marchi E, Pileri S, Baccarani M: Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer; 2004 May 15;100(10):2190-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma is a specific clinicopathologic entity with gastric and nongastrointestinal site involvement.
  • The authors reported the clinical outcome of patients with Stage IE nongastrointestinal MALT lymphoma treated with a frontline fludarabine-containing regimen or with a regimen containing cyclophosphamide, vincristine, and prednisone (CVP).
  • METHODS: Between 1998 and 2001, 31 patients with Stage IE disease were referred to the Seràgnoli Institute of Hematology and Medical Oncology at the University of Bologna (Bologna, Italy).
  • Presenting sites included periorbital soft tissue (n = 8), lung (n = 5), skin (n = 5), salivary glands (n = 5), lacrimal glands (n = 5), and thyroid (n = 3).
  • Four patients, all treated with CVP, experienced disease recurrence and then achieved a second CR after FM salvage treatment.
  • No tumor recurrence was observed in patients with thyroid, lacrimal gland, or pulmonary lymphoma.
  • CONCLUSIONS: The fludarabine-containing FM regimen provided a relatively effective frontline (or salvage) treatment option for patients with nongastrointestinal Stage IE MALT lymphoma and probably was superior to CVP in terms of efficacy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA (Cytosine-5-)-Methyltransferase / antagonists & inhibitors. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Gastrointestinal Neoplasms. Humans. Male. Middle Aged. Prednisone / administration & dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139063.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


Advertisement
4. Sharma K, Rathi AK, Khurana N, Mukherji A, Kumar V, Singh K, Bahadur AK: A retrospective study of 18 cases of adenoid cystic cancer at a tertiary care centre in Delhi. Indian J Cancer; 2010 Oct-Dec;47(4):424-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of 18 cases of adenoid cystic cancer at a tertiary care centre in Delhi.
  • CONTEXT: Adenoid cystic carcinoma (ACC) is a rare neoplasm that usually arises from the salivary, lacrimal, or other exocrine glands.
  • AIM: To analyze the presentation and natural history of cases of adenoid cystic tumors of salivary glands in our institution; and to compare with the existing literature.
  • MATERIALS AND METHODS: Data on 18 patients of ACC of the salivary glands treated between 2004 and 2008 were reviewed with respect to clinical presentation, stage, and histology.
  • RESULTS: There were 8 cases of major salivary gland tumors (47%), of which 2 were in the submandibular and 6 were involving the parotid.
  • Ten patients (53%) had minor salivary gland involvement.
  • Two patients had metastasis at the time of presentation.
  • Radiotherapy was delivered to 16 patients and chemotherapy to 6 patients (concurrent, n = 3 and adjuvant, n = 3) and no adjuvant therapy was given to 2 patients.
  • No patient developed local or distant failure during the study duration.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. India. Male. Middle Aged. Neoplasm Staging. Oral Surgical Procedures. Radiotherapy. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21131757.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D: Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res; 2001 Nov 1;61(21):7811-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
  • Many members of the human kallikrein gene family were found to be differentially expressed in various malignancies and some are useful cancer diagnostic/prognostic markers.
  • KLK9 is a newly discovered human kallikrein gene that is expressed in several tissues including thymus, testis, spinal cord, salivary gland, ovary, and skin.
  • Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones in cancer cell lines.
  • Our purpose is to examine whether quantitative analysis of KLK9 expression has prognostic value in ovarian cancer.
  • We studied the expression of KLK9 by quantitative reverse transcription-PCR in 168 consecutive ovarian tumors of different stages, grades, and histological types, and correlated the expression with clinicopathological parameters, response to chemotherapy, and patients' survival.
  • When the Cox proportional hazard regression analysis was applied to subgroups of patients, KLK9 expression was found to be a significant predictor of progression-free survival in the subgroup of patients with low-grade tumors [hazard ratio (HR), 0.13; P = 0.0015], early stage (HR, 0.099; P = 0.031); and those with optimal debulking (HR, 0.26; P = 0.012).
  • Our results indicate that KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines.
  • Immmunohistochemically, human kallikrein protein (hK9) was localized in the cytoplasm, but not in the nuclei, of the epithelial cells of ovarian cancer tissues.
  • We conclude that KLK9 is a potential new independent favorable prognostic marker for early stage, low-grade, optimally debulked ovarian cancer patients.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Kallikreins / biosynthesis. Neoplasm Proteins. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11691797.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / Progestins; EC 3.4.21.- / KLK9 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


6. Zhao J, Wang MZ, Li LY, Zhang L, Zhong W: [Clinical features of pulmonary malignancies in patients younger than 30 years of age]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histories of smoking were noted in 10 patients (17.24%), and all of them were patients with epithelial tumor patients.
  • The mean time from the onset of disease to confirmed diagnosis was (5.98+/-8.95) months.
  • The proportions of advanced-stage patients (stage III B and IV) and moderate to poor-differentiated tumor accounted for 59.26% (16/27) and 77.8% (14/18), respectively in 27 patients with non-small cell lung cancer.
  • The proportion of tumors in limited stage was 72.73% in 11 patients with small cell lung cancer, and most patients (54.55) were not sensitive to conventional chemotherapy.
  • In 6 patients with carcinoid, 4 patients were central and the other 2 patients were peripheral, and all of them presented as Cushing syndrome; CgA, AE1/AE3, Syn, and NSE were positive in immunohistochemical staining; and surgical operation was the main treatment for them.
  • In 6 patients with carcinomas of salivary gland type, all cases were central; no lymph nodes metastasis was found in the postoperative specimen; and surgical operation was also the main treatment for these patients.
  • In 3 patients with primitive neuroectodermal tumors, the tumors were highly malignant and invasive, and the development of primitive neuroectodermal tumors was closely related with pleura.
  • Immunohistochemical staining showed that the tumor cells were positive for CD99.
  • Multiple nodules in bilateral lungs were presented in 2 patients with anaplastic large cell lymphomas, in which CD30 was positive in tumor cells; chemotherapy was the main therapy for these two patients.
  • In one patient with synovial sarcoma, the tumor was giant and highly malignant and invasive; it was divided into many cavities filled with bloody fluid and white cheese-like substances; immunohistochemical analysis showed positive vimentin and AE1/AE3.
  • The treatment strategy should be based on the specific conditions of each patient.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450548.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Vattemi E, Graiff C, Sava T, Pedersini R, Caldara A, Mandarà M: Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther; 2008 Mar;8(3):393-402
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapies for recurrent and/or metastatic salivary gland cancers.
  • Salivary gland carcinomas are rare cancers, comprising 1-5% of head and neck cancers.
  • The most commonly histopathologic types are mucoepidermoid cancer, adenoid cystic cancer and adenocarcinomas.
  • Malignant salivary gland tumors generally present as painless, slow-growing tumors that are indistinguishable from benign tumors.
  • Surgery is the principal treatment and is curative in early stage.
  • Radiation therapy should be considered in most patients after surgical resection.
  • Chemotherapy is reserved for palliative treatment of metastatic disease but results are disappointing.
  • Recent studies have investigated the role of targeted therapies in a palliative setting.
  • Multicentre cooperative group clinical trials are required to assess novel therapies to maximize patient resources in this uncommon tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local. Salivary Gland Neoplasms
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Hormonal / therapeutic use. Benzamides. Boronic Acids / therapeutic use. Bortezomib. Cetuximab. Humans. Imatinib Mesylate. Neoplasm Metastasis. Palliative Care. Piperazines / therapeutic use. Pyrazines / therapeutic use. Pyrimidines / therapeutic use. Quinazolines / therapeutic use. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366287.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Benzamides; 0 / Boronic Acids; 0 / Piperazines; 0 / Pyrazines; 0 / Pyrimidines; 0 / Quinazolines; 0VUA21238F / lapatinib; 69G8BD63PP / Bortezomib; 8A1O1M485B / Imatinib Mesylate; P188ANX8CK / Trastuzumab; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  • [Number-of-references] 56
  •  go-up   go-down


8. Hocwald E, Korkmaz H, Yoo GH, Adsay V, Shibuya TY, Abrams J, Jacobs JR: Prognostic factors in major salivary gland cancer. Laryngoscope; 2001 Aug;111(8):1434-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in major salivary gland cancer.
  • OBJECTIVE: To identify features of major salivary gland cancers that are prognostic for disease-free survival.
  • STUDY DESIGN: A retrospective study of 78 patients with major salivary gland cancer (64 parotid and 14 submandibular gland) who underwent surgery for definitive treatment from 1976 to 1996.
  • A select group of patients also received adjuvant radiation (56%) and/or chemotherapy (13%).
  • Age, gender, tumor site, T-stage, facial paralysis, histologic neck involvement, perineural invasion, and cancer grade were analyzed with respect to disease-free survival.
  • The role of adjuvant treatment in terms of clinical outcome was also investigated.
  • Examining clinical and histologic features one at a time, we found poorer prognosis was associated with submandibular tumors compared with parotid (P =.02), higher T-stage (P =.001), positive cervical nodes (P <.001), perineural invasion (P =.002), and high-grade or adenoid cystic tumors (P =.002).
  • Receipt of both adjuvant radiation and cisplatin-based chemotherapy (P =.05) was an independent predictor of longer disease-free survival.
  • Our limited data also suggest that adjuvant chemotherapy and radiation therapy may improve disease-free survival.
  • [MeSH-major] Parotid Neoplasms / mortality. Submandibular Gland Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568581.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Nieuw Amerongen AV, Veerman EC: Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer; 2003 Apr;11(4):226-31
Hazardous Substances Data Bank. PILOCARPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
  • In cancer patients, as in the general population, medication is the most common cause of xerostomia.
  • In general, saliva flow in these patients can be stimulated by mechanical or pharmacological stimulation of the salivary glands.
  • A specific group of patients are those receiving radiotherapy for malignant tumours in the head and neck region.
  • This treatment is inevitably associated with damages to the oral tissues, including the salivary glands, resulting in salivary gland hypofunction.
  • When residual secretory capacity is present, it is advisable to stimulate the salivary glands by mechanical or gustatory stimuli regularly in these patients as supportive oral care.
  • Alternatively, salivary flow can be stimulated by the use of cholinergic pharmaceutical preparations, such as pilocarpine or cevimeline.
  • After the radiation therapy is ended, a dental check-up should be done every 3 months to allow control of any incipient oral inflammation and dental decay.
  • When stimulation of salivary secretion fails, patients can be given palliative oral care in the form of application of mouthwashes and saliva substitutes.
  • Different types of saliva substitutes are now commercially available, containing different polymers as thickening agents, e.g. carboxymethylcellulose (Oralube and Glandosane), polyacrylic acid, and xanthan gum (Xialine).
  • Recent developments, which are, however, still in the experimental stage, are bio-active saliva substitutes and mouthwashes containing antimicrobial peptides to protect the oral tissues against microbial colonization and to suppress and to cure mucosal and gingival inflammation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy / adverse effects. Thiophenes. Xerostomia / etiology. Xerostomia / therapy
  • [MeSH-minor] Acupuncture Therapy. Chewing Gum. Diet / methods. Flavoring Agents / therapeutic use. Humans. Muscarinic Agonists / therapeutic use. Oral Hygiene / methods. Palliative Care / methods. Parasympathomimetics / therapeutic use. Pilocarpine / therapeutic use. Quinuclidines / therapeutic use. Saliva / secretion. Salivary Glands / drug effects. Salivary Glands / radiation effects

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CEVIMELINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Support Care Cancer. 2003 Apr;11(4):199-200 [12673457.001]
  • (PMID = 12673460.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chewing Gum; 0 / Flavoring Agents; 0 / Muscarinic Agonists; 0 / Parasympathomimetics; 0 / Quinuclidines; 0 / Thiophenes; 01MI4Q9DI3 / Pilocarpine; K9V0CDQ56E / cevimeline
  • [Number-of-references] 45
  •  go-up   go-down


10. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: [Malignant minor salivary gland tumors of the larynx]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):40-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant minor salivary gland tumors of the larynx].
  • OBJECTIVE: To study the clinical features, treatment and prognosis of malignant minor salivary gland tumors of the larynx.
  • METHODS: Treatment and outcome were retrospectively analyzed in a consecutive series of 15 patients with malignant minor salivary gland tumors of the larynx treated in this hospital from 1959 to 2005.
  • Ten patients (66.7%) had adenoid cystic carcinoma and 2 (13.3%) had adenocarcinoma.
  • The other three patients had mucoepidermoid carcinomas, polymorphic adenocarcinoma and base cell carcinoma respectively.
  • Fourteen had surgery (7 with adjuvant radiotherapy) and one was treated with radiotherapy plus chemotherapy.
  • Five patients were found to have recurrent disease, 4 of whom underwent salvage surgery, 1 of whom had palliation radiotherapy.
  • Five patients have no evidence of disease, 1 of whom had surgery alone, 4 of whom were treated with surgery plus radiotherapy.
  • The other 4 patients were lost to follow-up after treatment (ranging from 2 years to 16 years).
  • Seven patients developed recurrent disease, 1 of whom had local recurrence alone, 1 had regional recurrence alone, 2 had distant metastases alone, and 3 had local and distant metastases.
  • CONCLUSIONS: Minor salivary gland carcinomas of the larynx are rare and they are prone to the local recurrence and the distant metastasis in advanced stage.
  • Distant metastases remain the principal cause of treatment failure.
  • Surgery is the primary treatment modality used in most cases and the radiotherapy combining surgery has better local and regional control rate.
  • [MeSH-major] Laryngeal Neoplasms / therapy. Salivary Gland Neoplasms / therapy. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484987.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Fu ZC, Zhang B, Fu ZJ: As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland. Med Hypotheses; 2010 Dec;75(6):490-1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland.
  • Adenoid cystic carcinoma (ACC) is an uncommon tumor of the head and neck that may occur in any salivary gland tissue.
  • Discouraging treatment outcomes may be related to perineural spread, loco regional invasion, and an unusually high incidence of metastatic potential.
  • It presents a number of challenges related to facial nerve management and disease extension into surrounding soft tissue and bony compartments.
  • ACC mostly occurring in the major and minor salivary glands, has some unique characteristics such as slow growth, diffuse invasion, and high incidence of distant metastasis.
  • It is a high malignant carcinoma characterized by intensive local invasion and insidious distant metastasis to the lung at an early stage, which is responsible for a poor long-term survival rate.
  • The main clinical treatment to adenoid cystic carcinoma depended on surgical operation in the past.
  • However, it was not so easy to completely excise adenoid cystic carcinoma which resulting in the residual of tumor cells.
  • Adenoid cystic carcinoma is not sensitive to conventional chemotherapeutics, so it is necessary to explore a new kind of drug which possesses inhibition and killing effects to this tumor.
  • Arsenic trioxide (A(S2)O(3), ATO), a trivalent inorganic arsenite, has been proved to be an effective therapeutic agent against acute promyelocytic leukemia.
  • Numerous reports have revealed that arsenite exerts its therapeutic activity by induction of apoptosis.
  • It also induces apoptosis in a variety of cancer cells over a wide dose range.
  • A(S2)O(3) may become a treatment option for adenoid cystic carcinoma of salivary gland.
  • [MeSH-major] Apoptosis / drug effects. Arsenicals / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Growth Inhibitors / therapeutic use. Oxides / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656411.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Growth Inhibitors; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


12. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol; 2005 Jan 20;23(3):585-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
  • PURPOSE: This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit.
  • A high level of c-kit expression has been identified in more than 90% of ACCs.
  • PATIENTS AND METHODS: In a single-arm, two-stage, phase II clinical trial, adult patients with unresectable or metastatic ACC measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid.
  • Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy.
  • CONCLUSION: Because of the lack of activity, the study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted.
  • Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC.
  • Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Benzamides. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • (PMID = 15659505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM 17102-01; United States / NCI NIH HHS / CM / N01 CM 17107-01
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


13. Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W: The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Support Care Cancer; 2008 Feb;16(2):171-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer.
  • INTRODUCTION: Xerostomia is a common complication of radiotherapy for head and neck cancer because irreparable damage is caused to the salivary glands if they are included in the radiation fields.
  • The aim of the study was to evaluate the degree of xerostomia in survivors of head and neck cancer and to determine its impact on quality of life.
  • METHODS AND MATERIALS: A xerostomia questionnaire consisting of three parts (xerostomia score, quality of life survey, and visual analogue scale) was completed by 75 head and neck cancer patients, more than 6 months after radiotherapy and without evidence of disease.
  • The emotional impact of xerostomia was significant, causing worry (64%), tension (61%), or feelings of depression (44%).
  • Furthermore, patients reported problems with talking to (60%) or eating with (54%) other people and to feel restricted in amount and type of food (65%).
  • Quality of life was influenced by T classification, clinical stage, a higher radiation dose or the use of concomitant chemotherapy, but was independent of the interval since the end of radiotherapy.
  • CONCLUSIONS: Xerostomia after radiotherapy for head and neck cancer is extremely common and significantly affects quality of life.
  • No recuperation is seen over time, and the use of concomitant chemotherapy significantly increases the oral complications of radiation.
  • These results warrant the continuing efforts put into the development of salivary gland-sparing radiotherapy techniques and effective treatments of radiation-induced xerostomia.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Salivary Glands / radiation effects. Severity of Illness Index. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2001 Feb;22(2):225-31 [11258410.001]
  • [Cites] Support Care Cancer. 2003 Apr;11(4):226-31 [12673460.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1839-47 [16750911.001]
  • [Cites] Head Neck. 1999 Jan;21(1):1-11 [9890345.001]
  • [Cites] Radiother Oncol. 2002 May;63(2):203-11 [12063010.001]
  • [Cites] Head Neck. 1997 May;19(3):169-75 [9142514.001]
  • [Cites] Laryngoscope. 1996 Sep;106(9 Pt 1):1084-8 [8822710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1006-9 [15964708.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2525-34 [17078052.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Head Neck. 2005 May;27(5):421-8 [15782422.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1082; author reply 1082-3 [14648868.001]
  • [Cites] Head Neck. 1993 Nov-Dec;15(6):485-96 [8253555.001]
  • [Cites] Laryngoscope. 2004 Nov;114(11):1977-81 [15510026.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):659-64 [15936542.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):445-53 [16839705.001]
  • [Cites] Support Care Cancer. 1997 Jul;5(4):281-8 [9257424.001]
  • [Cites] Head Neck. 2001 May;23(5):389-98 [11295813.001]
  • [Cites] Head Neck. 2002 Aug;24(8):737-47 [12203798.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(5):308-12 [9368726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):847-56 [8138437.001]
  • [Cites] Radiother Oncol. 2004 Dec;73(3):297-306 [15588874.001]
  • [Cites] Radiat Oncol. 2007 Jan 05;2:3 [17207274.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Jul;31B(4):235-41 [7492919.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):329-35; discussion 335-6 [10722005.001]
  • [Cites] Support Care Cancer. 2007 Dec;15(12):1429-36 [17235501.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 3):4-7 [10718406.001]
  • [Cites] Radiology. 2005 May;235(2):629-34 [15858103.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):226-34 [12903012.001]
  • (PMID = 17618467.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


14. Dragnev KH, Petty WJ, Memoli V, Black W, Williams I, Rigas JR, Dmitrovsky E: A phase I/II study of bexarotene (B) and erlotinib (E): A novel targeted combination therapy for lung cancer and other aerodigestive tract (ADT) tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):3092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of bexarotene (B) and erlotinib (E): A novel targeted combination therapy for lung cancer and other aerodigestive tract (ADT) tumors.
  • Treatment of BEAS-2B human bronchial epithelial cells (HBEC) with tobacco carcinogens enhanced cyclin D1 and epidermal growth factor receptor (EGFR) expression.
  • Similar effects were noted with the rexinoid (B), bypassing the need for intact RAR-β signaling often deregulated in lung cancer.
  • RESULTS: Eight pts were enrolled, accrual continues -stage IV NSCLC (6), laryngeal (1), salivary gland (1).
  • 7 patients had prior chemotherapy.
  • There was 1 partial response for over 7 months (NSCLC), 1 minor response (bronchoalveolar), 1 stable disease (NSCLC), 3 progression (2 NSCLC, 1 salivary), 1 too early for evaluation and 1 nonevaluable.
  • CONCLUSIONS: Preliminary results indicate this is a well-tolerated regimen with activity in lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol; 2004 Jan 1;22(1):69-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
  • PURPOSE: We report the 5-year survival and late toxicity results of a randomized clinical trial, which showed a 3-year improvement in overall survival and locoregional control of stage III or IV oropharynx carcinoma, using concomitant radiochemotherapy (arm B), compared with standard radiotherapy (arm A).
  • PATIENTS AND METHODS: A total of 226 patients were entered onto a phase III multicenter randomized trial comparing radiotherapy alone (70 Gy in 35 fractions; arm A) with concomitant radiochemotherapy (70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and fluorouracil; arm B).
  • Five-year late toxicity was evaluated using National Cancer Institute Common Toxicity Criteria for neurological toxicity, hearing, taste, mandibula, and teeth damage, and Radiation Therapy Oncology Group toxicity criteria for skin, salivary gland, and mucosa.
  • Stage IV, hemoglobin level lower than 125 g/L, and standard treatment were independent prognostic factors of short survival and locoregional failure by univariate and multivariate analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Prognosis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jan 1;22(1):19-22 [14657230.001]
  • (PMID = 14657228.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Pajor A, Murlewska A, Józefowicz-Korczyńska M: [Tonsillar carcinoma--clinical assessment and analysis of treatment results]. Otolaryngol Pol; 2002;56(3):319-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tonsillar carcinoma--clinical assessment and analysis of treatment results].
  • The aim of the study was an evaluation of the clinical signs and treatment results of the patients with tonsillar cancer treated in the ENT Clinic Medical University in Łódź during 10 years (1985-1994).
  • Twenty four patients (55%) had tumor with T3-T4 stage and 21 patients (52.5%)--palpable lymph neck nodes.
  • The most frequent treatment modality was combined therapy (surgery with radio/chemotherapy) introduced in 25 persons (62.5%), surgery alone was performed in 10 cases (25%).
  • Distant metastases developed in 6 patients (15%) and the second primary neoplasm in 5 patients (12.5%).
  • We stress the importance of careful clinical assessment before planning the treatment.
  • [MeSH-major] Carcinoma, Squamous Cell. Tonsillar Neoplasms
  • [MeSH-minor] Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Combined Modality Therapy. Disease-Free Survival. Humans. Radiotherapy, Adjuvant. Retrospective Studies. Salivary Gland Neoplasms / radiotherapy. Salivary Gland Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162020.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem; 2009;44(1):29-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of metallothionein in oncogenesis and cancer prognosis.
  • The antiapoptotic, antioxidant, proliferative, and angiogenic effects of metallothionein (MT)-I+II has resulted in increased focus on their role in oncogenesis, tumor progression, therapy response, and patient prognosis.
  • Studies have reported increased expression of MT-I+II mRNA and protein in various human cancers; such as breast, kidney, lung, nasopharynx, ovary, prostate, salivary gland, testes, urinary bladder, cervical, endometrial, skin carcinoma, melanoma, acute lymphoblastic leukemia (ALL), and pancreatic cancers, where MT-I+II expression is sometimes correlated to higher tumor grade/stage, chemotherapy/radiation resistance, and poor prognosis.
  • However, MT-I+II are downregulated in other types of tumors (e.g. hepatocellular, gastric, colorectal, central nervous system (CNS), and thyroid cancers) where MT-I+II is either inversely correlated or unrelated to mortality.
  • Large discrepancies exist between different tumor types, and no distinct and reliable association exists between MT-I+II expression in tumor tissues and prognosis and therapy resistance.
  • This review aims at discussing the role of MT-I+II both as a prognostic marker for survival and therapy response, as well as for the hypothesized role of MT-I+II as causal oncogenes.
  • [MeSH-major] Biomarkers, Tumor. Metallothionein / physiology. Neoplasms / diagnosis. Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348910.001).
  • [ISSN] 0079-6336
  • [Journal-full-title] Progress in histochemistry and cytochemistry
  • [ISO-abbreviation] Prog Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9038-94-2 / Metallothionein
  • [Number-of-references] 203
  •  go-up   go-down


18. Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, Schultze-Mosgau S, Altendorf-Hofmann A: Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol; 2010 Jan;136(1):55-63
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database.
  • OBJECTIVE: To describe epidemiology and prognosis of head and neck cancer in Germany.
  • METHODS: We analyzed the Thuringian cancer registry database from 1996 to 2005.
  • 3,821 cases with primary head and neck cancer were evaluated for patient's characteristics, tumor stage, incidence, treatment, and trends in overall survival.
  • RESULTS: During the period 1996-2005, the incidence of oropharynx, hypopharynx, larynx, and salivary gland cancer increased significantly for males, and of oral cavity and hypopharynx cancer for females.
  • There was a significant trend using more multimodal therapy combining surgery, radiotherapy, and chemotherapy, and to use less radiotherapy as a single modality.
  • The median follow-up time of patients alive was 42 months.
  • The site-specific 5-year OS for lip, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, salivary gland, and nose/paranasal sinus cancer was 75.7, 42.6, 43.5, 45.9, 27.2, 57.3, 61.0, and 34.9%, respectively.
  • The multivariate analysis showed that male gender, age ≥ 60 years, therapy without surgery, higher T classification, N classification, and M classification were independent significant negative risk factors for OS (p < 0.0001).
  • Cancer of the oral cavity and of the hypopharynx had a significant lower OS than lip cancer (p = 0.012 and p = 0.044, respectively).
  • CONCLUSIONS: Many subsites of head and neck cancer have changing incidence.
  • Although treatment strategies have changed, outcome has not improved significantly from 1995 to 2006.
  • [MeSH-major] Databases, Factual / statistics & numerical data. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / therapy. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Public Health. 2006 Jun 06;6:146 [16756650.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2201-7 [9827726.001]
  • [Cites] Head Neck. 2005 Oct;27(10):843-50 [16161069.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Z Gerontol Geriatr. 2005 Feb;38(1):47-59 [15756487.001]
  • [Cites] Mayo Clin Proc. 2008 Apr;83(4):489-501 [18380996.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):221-8 [18544437.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Eur Addict Res. 2003 Oct;9(4):147-56 [12970583.001]
  • [Cites] Laryngorhinootologie. 2002 Jul;81(7):499-508 [12173061.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19568769.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Sullivan CA, Haddad RI, Tishler RB, Mahadevan A, Krane JF: Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope; 2005 Jun;115(6):958-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Chemoradiation-induced xerostomia affects approximately 40,000 head and neck cancer patients annually in the United States.
  • No human histopathologic or immunohistochemical data exist that characterize chemoradiation-related salivary gland damage.
  • The objective of this study was to describe the histopathologic and immunohistochemical features of the non-acute phase of human submandibular gland damage after chemoradiation therapy.
  • METHODS: Pathologic materials were retrieved from patients who had undergone neck dissection after protocol-driven chemoradiotherapy for stage IV head and neck cancer at a tertiary head and neck cancer institute.
  • RESULTS: Forty patients were identified who had undergone neck dissection an average of 11 weeks after treatment with induction chemotherapy and chemoradiation therapy for non-oral head and neck cancer.
  • CONCLUSIONS: Nonacute changes seen in human submandibular glands after chemoradiation therapy are compared to those seen in previously described irradiated animal and human models.
  • Primary dysfunction in humans appears to be related to a reduction in function and number of submandibular gland acinar cells.
  • The ductal system appears to be preserved after chemoradiation therapy.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Submandibular Gland / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Fibrosis / pathology. Humans. Immunohistochemistry. Inflammation / pathology. Male. Middle Aged. Neck Dissection. Xerostomia / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933500.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cohen AJ, Menter A, Hale L: Acupuncture: role in comprehensive cancer care--a primer for the oncologist and review of the literature. Integr Cancer Ther; 2005 Jun;4(2):131-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acupuncture: role in comprehensive cancer care--a primer for the oncologist and review of the literature.
  • Acupuncture is a popular complementary therapy for patients with cancer.
  • This article will provide current cancer treatment providers with information on acupuncture as well as the research conducted on cancer symptoms and side effects of cancer treatments.
  • Several studies have found that acupuncture significantly reduces the number of emesis (vomiting) episodes for patients receiving chemotherapy.
  • While studies on pain control vary due to the heterogeneity of pain, there are few studies investigating pain caused from cancer and the removal of cancerous tumors.
  • These studies, while promising, provide basic results that need further investigation for more definitive results.
  • Although relatively few studies have been done on anxiety and depression, several researchers have found acupuncture to be just as effective as or more effective than antidepressants for patients without cancer.
  • Studies on breathlessness, while small, have shown acupuncture to have a significant positive effect on chronic obstructive pulmonary disease, breathlessness associated with end-stage cancer, and asthma.
  • Researchers studying xerostomic individuals who have received salivary gland irradiation found significant positive results in salivary flow rates compared to baseline.
  • A recent pilot study showed improvement of chronic postchemotherapy fatigue following acupuncture treatments.
  • Many individuals with cancer have turned to acupuncture because their symptoms persisted with conventional treatments or as an alternative or complement to their ongoing treatments.
  • Despite the immense popularity in the community, few large randomized trials have been conducted to determine the effects acupuncture has on cancer symptoms and side effects of treatments.
  • [MeSH-major] Acupuncture Therapy / methods. Acupuncture Therapy / standards. Antineoplastic Agents / adverse effects. Neoplasms / therapy
  • [MeSH-minor] Anxiety / prevention & control. Combined Modality Therapy. Comprehensive Health Care. Depression / prevention & control. Humans. Pain / prevention & control. Pulmonary Disease, Chronic Obstructive / prevention & control. Randomized Controlled Trials as Topic. Vomiting / prevention & control

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911926.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-46934; United States / NCI NIH HHS / CA / CA58187; United States / NCI NIH HHS / CA / R25 CA49981
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 92
  •  go-up   go-down


21. Malek SN, Hatfield AJ, Flinn IW: MALT Lymphomas. Curr Treat Options Oncol; 2003 Aug;4(4):269-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucosa-associated lymphoid tissue (MALT) lymphomas occur in a variety of organs, including the orbit, conjunctiva, salivary glands, skin, thyroid gland, lungs, stomach, and intestine.
  • Diagnosis is made by pathologic evaluation of a tissue biopsy.
  • Staging includes a history and physical, chemistries, computed tomography scan, and bone marrow biopsy.
  • Treatment is tailored to organ involvement and stage at presentation.
  • Eradication of Helicobacter pylori using a triple anti-H. pylori regimen approved by the US Food and Drug Administration is standard therapy for all H. pylori-positive gastric MALT lymphomas.
  • Endoscopic ultrasound- and computed tomography-staged gastric MALT stage IE tumors will achieve a complete response with this approach in approximately 60% to 90% of patients (the more superficial the tumor, the better the response).
  • Patients with tumors that are T4 node-positive Musshoff stage IIE1 and IIE2 or tumors with adverse cytogenetics should receive radiotherapy or surgery with or without radiotherapy.
  • Tumors with a significant high-grade component or large cell tumors with a minor low-grade MALT component should receive CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based chemotherapy.
  • Localized MALT lymphomas of the orbit, conjunctiva, salivary glands, and thyroid gland are treated successfully with radiotherapy.
  • Surgery as first-line therapy for gastric MALT lymphomas was replaced by attempts at organ preservation.
  • In the past, margin-free surgical excision or tumor debulking followed by radiation therapy and chemotherapy has been highly effective for gastric MALT lymphomas.
  • Therefore, surgical excision of large cell or bulky tumors of the stomach, thyroid, lung, and salivary gland, followed by adjuvant radiotherapy or chemotherapy, may still be an important consideration in selected patients.
  • Disseminated MALT lymphomas are incurable and are treated primarily with chemotherapy according to symptoms.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2002 May;55(5):346-51 [11986338.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):50-5 [11753078.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1087-90 [9322502.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1916-21 [9586910.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):95-102 [11145257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1058-66 [11958902.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):997-1008 [11474283.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] Cancer Invest. 2002;20(7-8):1059-68 [12449739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):657-63 [11849787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1093-103 [10725618.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2541-4 [11895791.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(5):300-4 [7826922.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1600-9 [11250988.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):547-8 [12241663.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2524-9 [7595703.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:241-58 [11722987.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):559-62 [11237911.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):307-15 [10375087.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):928-34 [10533473.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2041-8 [11283137.001]
  • [Cites] Gut. 2001 Apr;48(4):454-60 [11247887.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1313-24 [8620403.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):97-104 [11902529.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4245-51 [11709568.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] J Pathol. 2001 Mar;193(3):318-24 [11241410.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):355-62 [7619750.001]
  • [Cites] Curr Gastroenterol Rep. 2000 Dec;2(6):494-8 [11079052.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):88-95 [10419446.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):454-7 [10945490.001]
  • (PMID = 12943607.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tijink BM, De Bree R, Van Dongen GA, Leemans CR: How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol; 2006 Oct;31(5):447-51
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keypoints * Chemo-electroporation therapy with bleomycin is a locoregional treatment modality for head and neck and skin cancer, with the potential to preserve function.
  • * In our institution, chemo-electroporation therapy is used for patients that can no longer be treated by surgery or radiotherapy, or for whom surgical treatment would be very extensive and thus declined by the patient.
  • * This paper describes in detail the technique of bleomycin-electroporation therapy.
  • * The main focus of the trial is to determine the safety, effectiveness, and burden of bleomycin-electroporation therapy for the patient.
  • * All 17 tumours responded to therapy.
  • * Based on the outcome of the clinical trial, bleomycin-electroporation therapy has the potential to become a valuable addition to the late-stage treatment options for patients with head and neck or skin tumours.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Electroporation / methods. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / secondary. Carcinoma, Basal Cell / therapy. Carcinoma, Merkel Cell / secondary. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melanoma / secondary. Melanoma / therapy. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Netherlands. Salivary Gland Neoplasms / secondary. Salivary Gland Neoplasms / therapy. Sarcoma / secondary. Sarcoma / therapy. Skin Neoplasms / secondary. Skin Neoplasms / therapy. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014460.001).
  • [ISSN] 1749-4478
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


23. Chang SM, Xing RD, Zhang FM, Duan YQ: Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Dis; 2009 Nov;15(8):570-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the levels of serum sCD44v6 in patients with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging and monitoring treatment response in these patients.
  • One week after treatment, venous blood was collected once again in 60 patients with oral and maxillofacial squamous cell carcinoma (OSCC).
  • The levels of serum sCD44v6 in patients with OSCC and salivary carcinoma showed no difference with those in control group (P > 0.05).
  • The sCD44v6 level in patients with stage III and IV disease was higher than that of patients with stage I and II and that of the control group, but the difference was not significant (P > 0.05).
  • Serum sCD44v6 levels in patients with OSCC after treatment became lower than that prevailed during pretreatment (P < 0.05).
  • Serum sCD44v6 may be a valuable marker in monitoring treatment response in patients with OSCC.
  • [MeSH-major] Antigens, CD44 / blood. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Head and Neck Neoplasms / blood. Mouth Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / blood. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / blood. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / surgery. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Reference Values. Salivary Gland Neoplasms / blood. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563418.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen
  •  go-up   go-down


24. Puri T, Singh K, Sharma DN, Khurana N: Epithelial-myoepithelial carcinoma of the base of tongue: pathology and management. Indian J Cancer; 2004 Jul-Sep;41(3):138-40
Genetic Alliance. consumer health - Myoepithelial carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-myoepithelial carcinoma of the base of tongue: pathology and management.
  • Epithelial-myoepithelial carcinoma is a rare tumor which makes up about 0.2% of epithelial neoplasms of the salivary glands; parotid gland being the most common primary site of origin.
  • The tumor may also very rarely originate in minor salivary glands of the base of the tongue.
  • Due to rarity of its occurrence, histogenesis and clear cut therapeutic guidelines are not defined.
  • The present report describes the case of a 48 year old male who was diagnosed to have a tubular variant of epithelial-myoepithelial carcinoma of the base of tongue, Stage T3 N0 M0 (Stage group III).
  • The patient was treated with neoadjuvant chemotherapy followed by radical radiotherapy (Rt) and is alive with no evidence of disease 14 months following end of treatment.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Epithelial-Myoepithelial Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15472415.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


25. Sakamoto K, Izumaru S, Kurita T, Miyajima Y, Nakashima T: [Clinical review of mucoepidermoid carcinomas]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Feb;108(2):142-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucoepidermoid carcinoma is a rare head and neck cancer tumor, composed of both mucous and epidermoid cells.
  • We retrospectively reviewed the case of 36 such patients hospitalized in the last 24 years (between 1978 and 2002) at Kurume University Hospital, focusing on origin, treatment, and treatment outcome.
  • In this study, 33 patients undergoing currative treatment were studied in detail.
  • Tumors originated in major salivary glands in 24 and in the oral cavity, paranasal cavity, and oropharynx in 3 each.
  • Salivary gland carcinomas were graded, clinically and histopathologically based on the criteria of Goode et al. as follows: low (n = 3), intermediate (n = 3), and high (n = 18).
  • Five-year overall survival was 64%, i.e., 56% in salivary gland malignancy, 67% in oral cavity malignancy, 100% in paranasal cavity malignancy and 100% in oropharynx malignancy.
  • Five-year survival was 71% in stage I, 83% in stage II, and 54% in stage IV.
  • In 31 patients not undergoing chemotherapy, 6 died of distant metastasis.
  • These results emphasize the necessity of radiotherapy and chemotherapy after surgical treatment for head and neck mucoepidermoid carcinoma.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765727.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement